Our results support that secondary mutations in the ROS1 kinase domain are the major molecular mechanisms of crizotinib resistance in patients with ROS1-rearranged NSCLC, particularly those with extracranial progression. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.